Roth Capital Previews Preclinical PRESERVATION-1 Data; Affirms BioLineRx (BLRX) at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
UPDATE: JMP Securities Starts BioLineRx (BLRX) at Market Outperform
June 22, 2015 7:47 AM EDT(Updated - June 22, 2015 8:58 AM EDT)
JMP Securities initiated coverage on BioLineRx (NASDAQ: BLRX) with a Market Outperform rating and a price target of $5.00. Analyst Michael King Jr thinks investors are undervaluating the company's pipeline, given four of six assets are in phase II... More
